22717-55-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-chlorosalicylate is used as an active ingredient for its antiseptic, disinfectant, and anti-inflammatory properties, contributing to the development of medications that address various health conditions.
Used in Cosmetic Industry:
Methyl 4-chlorosalicylate is used as a key component in cosmetic formulations, leveraging its antiseptic and anti-inflammatory properties to enhance the effectiveness of skincare and personal care products.
However, it is important to note that exposure and consumption of Methyl 4-chlorosalicylate could lead to certain health hazards, indicating the need for careful management and handling in both industries.

InChI:InChI=1/C8H7ClO3/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 5106-98-9 4-chlorosalicylic acid 
• 119-36-8 methyl salicylate 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 69-72-7 salicylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 143277-37-6 4-chloro-2-hydroxy-benzoic acid-(2-hydroxy-ethylamide) 
• 61799-78-8 4-chloro-N,2-dihydroxybenzamide 
• 929301-82-6 methyl 4-chloro-2-[(2-methylprop-2-en-1-yl)oxy]benzoate 
• 212892-02-9 methyl 4-chloro-2-(((trifluoromethyl)sulfonyl)oxy)benzoate 
• 64917-81-3 4-chloro-2-hydroxybenzyl alcohol 
• 949570-69-8 methyl 4-chloro-2-(4-(2-methoxy-2-oxoethyl)-2-nitrophenoxy)benzoate 
• 796851-66-6 methyl 4-chloro-2-(2-ethoxy-2-oxoethoxy)benzoate 
• 131210-59-8 4-chloro-2-(1-methoxycarbonyl-ethoxy)-benzoic acid methyl ester 
• 276884-67-4 methyl thiomethyl ether 
• 1187383-45-4 5-(2'-methoxycarbonyl-5'-chlorophenoxy)furfural 
• 78955-90-5 methyl 4-chloro-2-methoxybenzoate 
• 1235837-73-6 methyl 4-chloro-2-(2-(5-hydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)acetoxy)benzoate 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 3260-78-4 6-chlorobenzofuran-3(2H)-one 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel 5,6,7-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

5,6,7-Trimethoxy flavonoid salicylate derivatives were designed by the joining of three important pharmacophores (TMP, flavonoid, and SA) according to the combination principle. A series of novel trimethoxy flavonoid salicylate derivatives were synthesized and their in vitro anti-tumor activities were evaluated. Among these derivatives, compound 7f exhibited excellent antiproliferative activity against HGC-27 cells and MGC-803 cells with IC50 values of 10.26 ± 6.94 μM and 17.17 ± 3.03 μM, respectively. Subsequently, the effects on cell colony formation (clonogenic survival assay), cell migration (wound healing assay), cell cycle distribution (PI staining assay), cell apoptosis (Hoechst 33258 staining assay and annexin V-FITC/PI dual staining assay), lactate level (lactate measurement), microtubules disarrangement (immunofluorescence staining analysis) and docking posture (molecular docking simulation) were determined. Further western blot analysis confirmed that compound 7f could effectively down-regulate the expression of glycolysis-related proteins HIF-1α, PFKM and PKM2 and tumor angiogenesis-related proteins VEGF. Overall, these studies suggested that compound 7f, as the representative compound of those, might be a promising candidate for the treatment of gastric cancer and deserved the further studies.

METHOD FOR SYNTHESIZING COMPOUND FOR ORGANIC ELECTRONIC ELEMENT AND COMPOUND PRODUCED BY THE SAME

The present invention relates to a method for synthesizing a compound for an organic electronic element, which provides a method for synthesizing a fluorene derivative. Provided in an embodiment of the present invention for achieving the purpose is a meth

INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically accept

Design, synthesis, and preliminary biological evaluation of 3′,4′,5′-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

According to the pharmacophore combination principle, a set of new 3′,4′,5′-trimethoxy flavonoid salicylate derivatives were designed, synthesized, and evaluated for biological activity. The cytotoxicity evaluation revealed that compound 10v exhibited higher potency than 5-Fu against HCT-116 cells. Preliminary biological activity studies showed that compound 10v could inhibit the colony formation and migration of HCT-116 cells. Besides, the Hoechst 33258 staining assay and flow cytometry revealed that treatment with compound 10v induced the apoptosis of HCT-116 cells in a concentration-dependent manner, while it had no effect on their cell cycle. The WB analysis suggested that HIF-1α, tubulin, HK-2, and PFK might be the potential pharmacophore targets of compound 10v. Tubulin was a potential drug target for compound 10v, which was explained by analyzing the crystal structure of compound 10v complexed with tubulin. These results indicated that compound 10v might be a promising anti-tumor agent candidate, deserving further optimization and evaluation.

Microwave-Assisted Synthesis of Benzofuran-3(2H)-ones

A new method for the synthesis of benzofuran-3(2H)-ones under microwave conditions was developed. The reaction conditions were screened, and the scope of benzoate substrates was investigated. The results showed that our method could provide rapid access to these important dihydrobenzofuranones in 43% to 58% yields.

Development of a synthetic route towards N4,N9-disubstituted 4,9-diaminoacridines: On the way to multi-stage antimalarials

A multi-step synthetic route towards N4,N9-disubstituted 4,9-diaminoacridines that, to the best of our knowledge, has no precedence in the literature, has been developed. The target structures are likely to reveal interesting biological activities in the near future, not only due to their mepacrine-like core, but also because they embed simultaneously the pharmacophores of chloroquine and primaquine, antimalarial drugs that act at different stages of malaria infection.

MODIFIED COMPOUND OF ANDROGRAPHOLIDE

The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

Gold promoted arylative cyclization of alkynoic acids with arenediazonium salts

Alkynoic acids derived from salicylic acid and analogues undergo arylative cyclization with arenediazonium salts promoted by gold in the absence of external ligands. The reaction is thermally induced and proceeds even in the absence of light. A difference in regioselectivity has been found compared with that observed in the cycloisomerization process of the same type of compounds.

C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to C-3 novel triterpenone with C-17 reverse amide compounds of Formula (I); and pharmaceutically acceptable salts thereof, wherein ring Formula (II), R1, R2, R3, R4, R5, R6, R7, 'n' and 'm' are as defined in Formula (I). The invention also relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.